Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.

Toshiro Shirakawa, Akinobu Gotoh, Zhujun Zhang, Chinghai Kao, Leland W K Chung, Thomas Gardner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVES: To develop a new toxic gene therapy using the tissue-specific human chorionic gonadotropin-beta (hCG-beta) promoter for testicular cancer. Although most patients presenting with disseminated testicular tumor are cured through the use of chemotherapy with or without surgery, those patients with relapse after initial therapy present a difficult clinical problem. The serum tumor marker hCG-beta is frequently elevated in patients with testicular cancer, and the pretreatment and post-treatment levels of serum hCG-beta are highly predictive of treatment outcome. METHODS: Human testicular embryonal carcinoma cell line, NEC 8, a human prostate cancer cell line, PC-3, and a human bladder cancer cell line, WH, were used in this study. A transient expression experiment was used to analyze the activity of a 729-bp hCG-beta promoter in all three cell lines. A recombinant adenovirus carrying thymidine kinase (Ad-hCG-beta-TK) under control of the hCG-beta promoter was generated. The tissue-specific activity of Ad-hCG-beta-TK was tested in vitro and in vivo. RESULTS: The hCG-beta promoter had significantly greater activity in the hCG-beta-producing cell line (NEC 8) than in the non-hCG-beta-producing cell lines (PC-3 and WH). In vitro, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 growth but not PC-3 or WH cell growth. In vivo, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 subcutaneous tumor growth in nude mice. CONCLUSIONS: In this study, we explored the possibility of developing a new therapeutic agent to target and induce the killing of testicular germ cell tumor selectively by using tissue-specific hCG-beta promoters.

Original languageEnglish (US)
Pages (from-to)613-618
Number of pages6
JournalUrology
Volume63
Issue number3
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Chorionic Gonadotropin, beta Subunit, Human
Poisons
Testicular Neoplasms
Chorionic Gonadotropin
Genetic Therapy
Cell Line
Acyclovir
Growth
Embryonal Carcinoma Stem Cells
Thymidine Kinase
Tumor Biomarkers
Urinary Bladder Neoplasms
Adenoviridae
Nude Mice

ASJC Scopus subject areas

  • Urology

Cite this

Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer. / Shirakawa, Toshiro; Gotoh, Akinobu; Zhang, Zhujun; Kao, Chinghai; Chung, Leland W K; Gardner, Thomas.

In: Urology, Vol. 63, No. 3, 03.2004, p. 613-618.

Research output: Contribution to journalArticle

Shirakawa, Toshiro ; Gotoh, Akinobu ; Zhang, Zhujun ; Kao, Chinghai ; Chung, Leland W K ; Gardner, Thomas. / Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer. In: Urology. 2004 ; Vol. 63, No. 3. pp. 613-618.
@article{f4a1fae784d245c1ab147b3e8394c98f,
title = "Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.",
abstract = "OBJECTIVES: To develop a new toxic gene therapy using the tissue-specific human chorionic gonadotropin-beta (hCG-beta) promoter for testicular cancer. Although most patients presenting with disseminated testicular tumor are cured through the use of chemotherapy with or without surgery, those patients with relapse after initial therapy present a difficult clinical problem. The serum tumor marker hCG-beta is frequently elevated in patients with testicular cancer, and the pretreatment and post-treatment levels of serum hCG-beta are highly predictive of treatment outcome. METHODS: Human testicular embryonal carcinoma cell line, NEC 8, a human prostate cancer cell line, PC-3, and a human bladder cancer cell line, WH, were used in this study. A transient expression experiment was used to analyze the activity of a 729-bp hCG-beta promoter in all three cell lines. A recombinant adenovirus carrying thymidine kinase (Ad-hCG-beta-TK) under control of the hCG-beta promoter was generated. The tissue-specific activity of Ad-hCG-beta-TK was tested in vitro and in vivo. RESULTS: The hCG-beta promoter had significantly greater activity in the hCG-beta-producing cell line (NEC 8) than in the non-hCG-beta-producing cell lines (PC-3 and WH). In vitro, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 growth but not PC-3 or WH cell growth. In vivo, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 subcutaneous tumor growth in nude mice. CONCLUSIONS: In this study, we explored the possibility of developing a new therapeutic agent to target and induce the killing of testicular germ cell tumor selectively by using tissue-specific hCG-beta promoters.",
author = "Toshiro Shirakawa and Akinobu Gotoh and Zhujun Zhang and Chinghai Kao and Chung, {Leland W K} and Thomas Gardner",
year = "2004",
month = "3",
language = "English (US)",
volume = "63",
pages = "613--618",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.

AU - Shirakawa, Toshiro

AU - Gotoh, Akinobu

AU - Zhang, Zhujun

AU - Kao, Chinghai

AU - Chung, Leland W K

AU - Gardner, Thomas

PY - 2004/3

Y1 - 2004/3

N2 - OBJECTIVES: To develop a new toxic gene therapy using the tissue-specific human chorionic gonadotropin-beta (hCG-beta) promoter for testicular cancer. Although most patients presenting with disseminated testicular tumor are cured through the use of chemotherapy with or without surgery, those patients with relapse after initial therapy present a difficult clinical problem. The serum tumor marker hCG-beta is frequently elevated in patients with testicular cancer, and the pretreatment and post-treatment levels of serum hCG-beta are highly predictive of treatment outcome. METHODS: Human testicular embryonal carcinoma cell line, NEC 8, a human prostate cancer cell line, PC-3, and a human bladder cancer cell line, WH, were used in this study. A transient expression experiment was used to analyze the activity of a 729-bp hCG-beta promoter in all three cell lines. A recombinant adenovirus carrying thymidine kinase (Ad-hCG-beta-TK) under control of the hCG-beta promoter was generated. The tissue-specific activity of Ad-hCG-beta-TK was tested in vitro and in vivo. RESULTS: The hCG-beta promoter had significantly greater activity in the hCG-beta-producing cell line (NEC 8) than in the non-hCG-beta-producing cell lines (PC-3 and WH). In vitro, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 growth but not PC-3 or WH cell growth. In vivo, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 subcutaneous tumor growth in nude mice. CONCLUSIONS: In this study, we explored the possibility of developing a new therapeutic agent to target and induce the killing of testicular germ cell tumor selectively by using tissue-specific hCG-beta promoters.

AB - OBJECTIVES: To develop a new toxic gene therapy using the tissue-specific human chorionic gonadotropin-beta (hCG-beta) promoter for testicular cancer. Although most patients presenting with disseminated testicular tumor are cured through the use of chemotherapy with or without surgery, those patients with relapse after initial therapy present a difficult clinical problem. The serum tumor marker hCG-beta is frequently elevated in patients with testicular cancer, and the pretreatment and post-treatment levels of serum hCG-beta are highly predictive of treatment outcome. METHODS: Human testicular embryonal carcinoma cell line, NEC 8, a human prostate cancer cell line, PC-3, and a human bladder cancer cell line, WH, were used in this study. A transient expression experiment was used to analyze the activity of a 729-bp hCG-beta promoter in all three cell lines. A recombinant adenovirus carrying thymidine kinase (Ad-hCG-beta-TK) under control of the hCG-beta promoter was generated. The tissue-specific activity of Ad-hCG-beta-TK was tested in vitro and in vivo. RESULTS: The hCG-beta promoter had significantly greater activity in the hCG-beta-producing cell line (NEC 8) than in the non-hCG-beta-producing cell lines (PC-3 and WH). In vitro, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 growth but not PC-3 or WH cell growth. In vivo, Ad-hCG-beta-TK with acyclovir significantly inhibited NEC 8 subcutaneous tumor growth in nude mice. CONCLUSIONS: In this study, we explored the possibility of developing a new therapeutic agent to target and induce the killing of testicular germ cell tumor selectively by using tissue-specific hCG-beta promoters.

UR - http://www.scopus.com/inward/record.url?scp=2942631096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942631096&partnerID=8YFLogxK

M3 - Article

C2 - 15028478

AN - SCOPUS:2942631096

VL - 63

SP - 613

EP - 618

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -